益盛药业(002566) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 250,973,766.69, representing an increase of 11.28% compared to CNY 225,540,617.25 in the same period last year[4] - Net profit attributable to shareholders was CNY 28,702,562.15, up by 5.41% from CNY 27,229,639.30 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.0867, reflecting a growth of 5.35% from CNY 0.0823[4] - Operating profit increased to ¥39,719,516.33, reflecting a growth of 18.3% from ¥33,666,091.21 in the last period[16] - Net profit for the current period was ¥31,391,147.16, a rise of 7.4% compared to ¥29,228,860.26 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 106.11%, reaching CNY 80,326,480.85 compared to CNY 38,973,399.49 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥80,326,480.85, significantly higher than ¥38,973,399.49 in the previous period[20] - Cash and cash equivalents at the end of the period totaled ¥435,152,569.03, compared to ¥200,989,827.14 at the end of the previous period[21] - The company's cash and cash equivalents increased to RMB 435,152,569.03 from RMB 343,263,877.76, representing a growth of approximately 27%[13] - The company reported a net increase in cash and cash equivalents of ¥91,888,691.27, contrasting with a decrease of ¥18,705,189.26 in the prior period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,012,881,593.88, a 1.56% increase from CNY 2,966,606,675.95 at the end of the previous year[4] - Current assets reached RMB 2,359,212,920.22, up from RMB 2,302,612,638.12, indicating an increase of about 2.5%[13] - Total liabilities stood at RMB 732,062,391.35, compared to RMB 717,178,620.58 at the beginning of the year, showing a slight increase of about 2.1%[14] - The company's total equity rose to RMB 2,280,819,202.53 from RMB 2,249,428,055.37, reflecting an increase of approximately 1.4%[14] - Short-term borrowings increased to RMB 470,447,708.34 from RMB 430,427,013.89, marking an increase of about 9.3%[14] Operating Costs and Expenses - Operating costs rose by 31.77% to CNY 70,618,510.44, primarily due to increased revenue[5] - Total operating costs amounted to ¥221,979,729.88, up 11.1% from ¥199,827,029.66 in the prior period[16] - Financial expenses decreased significantly by 71.27%, totaling CNY 749,875.57, attributed to increased interest income from agreement deposits[5] - Research and development expenses rose to ¥5,323,126.61, compared to ¥4,342,941.68 in the previous period, indicating a focus on innovation[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,625, with the largest shareholder holding 39.08% of the shares[8] - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[10] - The company aims to resolve the shareholding proxy issue in the shortest time possible while considering the impact on the secondary market[10] Regulatory Compliance - The company is focused on ensuring the accuracy and completeness of its financial disclosures following regulatory requirements[10] - The company has not undergone an audit for the first quarter report[22] Government Subsidies and Fair Value Gains - The company received government subsidies amounting to CNY 11,018,215.10, which are closely related to its normal business operations[5] - The company reported a 49.42% increase in fair value gains, amounting to CNY 1,160,582.03, influenced by changes in the value of financial products[5] - The company reported a decrease in inventory from RMB 1,603,100,929.50 to RMB 1,592,167,434.20, a reduction of approximately 0.7%[13]